Abstract

To assess the correlation of maternal serum glycosylated fibronectin level in preeclamptic pregnant women with severity of pre-eclampsia.
Methods: An 18-month prospective study was conducted at the Rajarajeshwari Medical College and Hospital (RRMCH), Bengaluru, in the department of obstetrics and gynaecology (Jan 2021 – May 2022). Twenty-five preeclamptic pregnant women ≥20 weeks gestation made up the anticipated sample size. The Lumella^TM PE test gadget was used to perform the maternal serum GlyFN test using the GlyFN POC device (from DiabetOmics, Inc.).
Results: There was statistically significant difference in severe pre-eclampsia between <=350 and >350 serum fibronectin values (P value <0.05). There were 93.75% (15 out of 16) severe pre-eclampsia cases in >350 serum fibronectin group where it was only 6.25% in <=350 group.
Conclusion: GlyFn POC test is a promising biochemical marker for severity of preeclampsia, and may be a useful adjunctive tool for rapid and accurate triage and intervention.